A Prospective Study of Pravastatin in the Elderly at Risk PROSPER: Screening Experience and Baseline CharacteristicsReportar como inadecuado

A Prospective Study of Pravastatin in the Elderly at Risk PROSPER: Screening Experience and Baseline Characteristics - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Current Controlled Trials in Cardiovascular Medicine

, 3:8

First Online: 20 May 2002Received: 21 January 2002Accepted: 20 May 2002DOI: 10.1186-1468-6708-3-8

Cite this article as: Ford, I., Blauw, G.J., Murphy, M.B. et al. Trials 2002 3: 8. doi:10.1186-1468-6708-3-8


BackgroundPROSPER was designed to investigate the benefits of treatment with pravastatin in elderly patients for whom a typical doctor might consider the prescription of statin therapy to be a realistic option.

MethodsThe PRO spective S tudy of P ravastatin in the E lderly at R isk PROSPER is a randomised, double blind, placebo-controlled trial to test the hypothesis that treatment with pravastatin 40 mg-day will reduce the risk of coronary heart disease death, non-fatal myocardial infarction, and fatal or non-fatal stroke in elderly men and women with pre-existing vascular disease or with significant risk of developing this condition.

ResultsIn Scotland, Ireland, and the Netherlands, 23,770 individuals were screened, and 5,804 subjects 2,804 men and 3,000 women, aged 70 to 82 years average 75 years and with baseline cholesterol 4.0–9.0 mmol-l, were randomised. Randomised subjects had similar distributions with respect to age, blood pressure, and body mass index when compared to the entire group of screenees, but had a higher prevalence of smoking, diabetes, hypertension, and a history of vascular disease. The average total cholesterol level at baseline was 5.4 mmol-l men and 6.0 mmol-l women.

ConclusionsCompared with previous prevention trials of cholesterol-lowering drugs, the PROSPER cohort is significantly older and for the first time includes a majority of women. The study, having achieved its initial goal of recruiting more than 5,500 elderly high-risk men and women, aims to complete all final subject follow-up visits in the first half of 2002 with the main results being available in the fourth quarter of 2002.

Keywordsclinical trial elderly pravastatin baseline characteristics 

Autor: Ian Ford - Gerard Jan Blauw - Michael B Murphy - James Shepherd - Stuart M Cobbe - Edward LEM Bollen - Brendan M Buckl

Fuente: https://link.springer.com/

Documentos relacionados